How should patients compare brand-name and compounded GLP-1 costs when using Medicare?

Medicare patients should compare their Part D plan's specific out-of-pocket costs for brand-name GLP-1s, if covered, against the fixed monthly price of compounded options.

Medicare Part D Coverage for Brand-Name GLP-1s

Medicare Part D plans may cover brand-name GLP-1 receptor agonists like Ozempic or Mounjaro when prescribed for their FDA-approved indication, type 2 diabetes. However, coverage for chronic weight management medications like Wegovy or Zepbound is explicitly excluded by law from standard Part D coverage.

Some Medicare Advantage or supplemental plans may offer additional benefits that cover weight loss drugs, but this is not standard. Patients must check their specific plan's formulary (list of covered drugs) to confirm coverage for any GLP-1 medication and the associated indication.

To check your coverage, contact your plan administrator directly or use the Medicare Plan Finder tool on Medicare.gov. Look for the specific drug name and note any requirements like prior authorization or step therapy, where you must try other medications first.

Out-of-Pocket Costs for Brand-Name GLP-1s on Medicare

If a GLP-1 is covered by your Part D plan for diabetes, your costs will vary throughout the year based on the four coverage stages. In 2024, you first pay 100% of costs until you meet your plan's deductible (up to $545).

After the deductible, you enter the Initial Coverage phase, where you typically pay a 25% coinsurance on the drug's price until total drug costs reach $5,030 for the year. For a drug with a list price of $1,000, your share would be about $250 per month.

Next is the Coverage Gap or "donut hole." Here, you'll pay 25% of the cost for brand-name drugs until your total out-of-pocket spending reaches $8,000. Finally, you enter Catastrophic Coverage, where your drug costs for the rest of the year are significantly lower or zero.

If the medication is not on your formulary, you are responsible for 100% of the list price, which can exceed $1,300 per month. Some manufacturers offer Patient Assistance Programs (PAPs) for low-income individuals, which may provide the drug at a lower cost or for free.

Understanding Compounded GLP-1 Medications

Compounded medications are prepared by licensed U.S. pharmacies to fill a prescription for a specific patient. These are prescribed by a healthcare provider when an FDA-approved drug is unavailable due to a shortage or if a patient cannot tolerate an inactive ingredient in the commercial version.

Crucially, compounded semaglutide and tirzepatide are not FDA-approved. They have not undergone the same rigorous testing for safety, efficacy, and quality as brand-name drugs like Wegovy or Zepbound. Patients should only obtain compounded medications through a physician-supervised program.

Because compounded medications are not commercial products, they are not covered by insurance plans, including Medicare. Patients pay for these medications directly as a cash expense. The cost is typically a fixed monthly fee that includes the medication, supplies, and clinical support.

Cost Comparison: Medicare vs. Compounded

When comparing costs, the primary difference is predictability. Physician-supervised compounding programs typically offer a flat monthly fee, often ranging from $299 to $599, which includes the medication and program access. This price is consistent and not subject to insurance deductibles or coverage gaps.

For a brand-name drug covered under Part D, the monthly cost fluctuates. It could start at $545 (to meet the deductible), then drop to around $250/month (coinsurance), and change again in the coverage gap. The total annual cost can be difficult to predict and may exceed several thousand dollars.

If a brand-name GLP-1 is not covered for weight loss, the comparison is simple: the full list price (often $1,000-$1,400 per month) versus the fixed monthly cost of a compounded medication. In this scenario, the compounded option presents a more accessible price point.

How to Evaluate Your Options

First, verify your specific Medicare Part D plan's formulary. Confirm if the desired GLP-1 is covered for your diagnosis (diabetes or weight loss). Call your insurer for the most accurate information.

If it is covered, use your plan's cost estimator tools to calculate your projected annual out-of-pocket expense, factoring in the deductible and coverage gap. Compare this annual total to the annual cost of a compounding program (e.g., $400/month x 12 = $4,800/year).

If you are seeking treatment for chronic weight management, you may find that both brand-name and compounded options represent an out-of-pocket expense. A physician-supervised telehealth program for medical [weight loss](/weight-loss) can help determine if a compounded medication is an appropriate option for you based on your health profile and financial considerations.

Bottom Line

For Medicare beneficiaries, brand-name GLP-1s are typically only covered for type 2 diabetes, leading to variable out-of-pocket costs throughout the year due to deductibles and coverage gaps. Weight loss drugs are generally not covered, resulting in high list-price expenses.

Compounded GLP-1s, which are not FDA-approved and not covered by insurance, offer a predictable, fixed monthly cost. Patients should carefully compare their plan's projected annual cost for a covered brand-name drug against the fixed annual cost of a physician-supervised compounding program.

This article is for informational purposes only and does not constitute medical advice.

Drafted by the GOAL.MD Authority Engine and approved editorially by GOAL.MD staff. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.